A computer tool tries to read tumor markers from brain MRI scans
Original title: Externally validated explainable 3D CNN ensemble model for non-invasive prediction of IDH and MGMT status in gliomas.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This is a computer tool tested on scans, not yet used by doctors.
The short version
Researchers built a computer tool that looks at MRI scans to guess two glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary tumor markers.
What was studied. A computer program learned from MRI scans of people with gliomas, a type of brain tumor. It tried to guess two tumor markers, called IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary and MGMT promoter methylation: MGMT is a gene whose protein repairs damage to a tumor's DNA. Methylation turns it down. Your report says how much, and your team uses that when they choose chemotherapy. The line between high and low is not settled. See the glossary, from regular scans alone.
What they found. For IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary, the tool did well in its first tests and fairly well on scans from a new group. For MGMT promoter methylation: MGMT is a gene whose protein repairs damage to a tumor's DNA. Methylation turns it down. Your report says how much, and your team uses that when they choose chemotherapy. The line between high and low is not settled. See the glossary, it looked fairly good at first but did poorly on the new group. The tool also showed which parts of the scan it used, and these made sense.
What this means, and what it doesn't
What it could mean: Someday, a tool like this might help doctors learn about a tumor from a regular MRI. For IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary, this is a small step in that direction. For MGMT promoter methylation: MGMT is a gene whose protein repairs damage to a tumor's DNA. Methylation turns it down. Your report says how much, and your team uses that when they choose chemotherapy. The line between high and low is not settled. See the glossary, the authors say scans alone are not enough yet.
What it doesn't mean: This does not mean doctors can use this tool today. It was only tested on collections of scans, not in real patient care. The MGMT promoter methylation: MGMT is a gene whose protein repairs damage to a tumor's DNA. Methylation turns it down. Your report says how much, and your team uses that when they choose chemotherapy. The line between high and low is not settled. See the glossary part did not hold up on new patients and needs more work. It does not change any treatment, and it is not a cure.
Source: PubMed, August 26, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.